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The current paradigm of diagnosing interstitial cystitis/painful bladder syndrome (IC/PBS) focuses largely
on the exclusion of other pathology and symptoms of urinary frequency, urgency, and pain, pressure, or
discomfort with bladder ﬁlling, and places less emphasis on diagnostic tests. Consequently, many experts
have suggested that urodynamic study (UDS) is not recommended for routine clinical use to establish IC/
PBS diagnosis. However, recent studies have demonstrated the correlations of UDS variables with clinical
symptoms, the results of a potassium sensitivity test, severity of glomerulations, and maximal bladder
capacity during cystoscopic hydrodistention. Moreover, a combination of UDS and potassium sensitivity
test has been shown to aid in differentiating IC/PBS in women with increased bladder sensation. All of
these facts suggest that there might be a role for UDS in the diagnosis of IC/PBS.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Interstitial cystitis/painful bladder syndrome (IC/PBS) is a clini-
cal diagnosis based on symptoms including urinary frequency, ur-
gency, and bladder pain, pressure, and/or discomfort in the absence
of other pathological ﬁndings [1e5]. Since diseases that cause
similar symptoms need to be excluded, patients with IC/PBS are
often diagnosed years after the onset of their symptoms [1,2,4].
Development of objective tests, including urodynamic study (UDS),
in the evaluation of patients with irritative voiding symptoms may
be beneﬁcial in the early diagnosis and, therefore, treatment of IC/
PBS. There is currently a paucity of literature addressing urody-
namics and its role in IC/PBS.
In the United States, IC/PBS affects about nine times as many
women as men [6]. Estimates of the prevalence rates of IC/PBS vary
widely, from 67 to 230 per 100,000 women having clinically con-
ﬁrmed disease [7,8]. Since IC/PBS cannot be cured, the goal of
treatment is largely based on symptomatic relief at present. A
certain percentage of patients treated have successful results for
a short time, but most patients experience symptom relapse inddhist Tzu Chi General Hos-
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ddhist Compassion Relief Tzu Chilong-term follow-up and need continual treatment with several
different therapeutic modalities [9].
The aim of this article is to provide a topical review from the
recent literature focusing on the role of UDS in the evaluation of IC/
PBS.
2. Deﬁnition of interstitial cystitis/painful bladder syndrome
According to the most recent American Urology Association
(AUA) guidelines, the deﬁnition of IC/PBS is: “An unpleasant sen-
sation (pain, pressure, discomfort) perceived to be related to the
urinary bladder, associated with lower urinary tract symptoms of
more than 6 weeks’ duration, in the absence of infection or other
identiﬁable causes” [10].
3. Pathophysiology of interstitial cystitis/painful bladder
syndrome
Although there are numerous hypotheses regarding the primary
cause of IC/PBS, no single etiology has been established, and most
experts believe it is a multifactorial process that starts with one of
several urological insults, such as immune-mediated injury, chronic
inﬂammation, deﬁcient bladder defenses, or obstruction of vascular
or lymphatic vessels [11]. The natural history of IC/PBS then in-
volves a cascade of events, in which bladder insult leads to epi-
thelial layer dysfunction, C-nerve ﬁber activation, and the
proliferation of mast cells [12]. Without appropriate treatment,Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
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cycle of progressively worsening tissue damage, scarring, and ﬁb-
rosis [13].
3.1. Glycosaminoglycan layer defect
A key concept currently accepted for describing the defect un-
derlying the observed pathophysiologies in IC/PBS is based on the
belief that breakdown of the glycosaminoglycan (GAG) layer (the
semipermeable protective coating that covers the bladder epi-
thelium and protects against leakage of urinary irritants such as
potassium and urea into the bladder wall) is the primary trigger of
the cascade. In a healthy bladder, this mucous layer acts as a barrier
that prevents damage to the underlying nerves and muscles and
impedes bacterial adherence. If the GAG layer is impaired or inef-
ﬁcient, the irritants in the urine are able to penetrate the bladder
wall, initiate the pathological cascade, damage tissue, cause pain,
and disrupt the normal reparative process of the GAG layer.
Addressing this altered permeability of the bladder epithelium has
become a focus for IC/PBS treatment strategies.
3.2. Neurogenic inﬂammation and spinal windup
Also contributing to this disease process is the concept of spinal
cord “windup”, the repetitive stimulation of C ﬁbers in the dorsal
horn and upregulation of sensory nerves in the bladder that cause
the characteristic pain of IC/PBS [12,14]. The ability to perceive pain
from internal organs is a function of the afferent sensory system,
which in some organs projects to the central nervous system,
thereby linking the viscera to the pain centers of the brain [15]. The
bladder has the highest neural density of tissues within the pelvis
[14]. A large group of visceral nerves are “silent” until a prolonged
noxious stimulus, such as inﬂammation, causes them to become
activated [15]. With ongoing stimulation from inﬂammation, dur-
ing which there is prolonged release of neurotransmitters such as
substance P, the threshold for neuronal stimulation decreases
(allodynia) so that the amount of stimulation required to send
a signal to the cerebral cortex is reduced [14].
As the neurological stimulation escalates because of hyper-
algesia and allodynia, conditions of widespread pain and dis-
comfort begin, and there may be progressive damage to the pelvic
ﬂoor or gastrointestinal organs, as well as gynecological and uri-
nary symptoms. Based on the duration and severity of these
alterations taking place within the dorsal horn, the changes can
become permanent; a process known as centralization. With this
neural upregulation, patients begin to experience exaggerated re-
ﬂex output and viscero-visceral hyperalgesia, and muscle spasticity
[14]. In these circumstances, the pain threshold is reduced so that
minimal contact can induce a response. In addition, pain in one
organwill cause discomfort in a neighboring organ because of their
shared innervation, leading to multiple pain generators and a self-
perpetuating cycle of pain. This progressive and variable regional
pain syndrome with multiorgan presentation complicates the
diagnosis of IC/PBS.
4. Evaluation of interstitial cystitis/painful bladder syndrome
Although the characteristic symptoms of IC/PBS are well docu-
mented, the substantial overlap with features of other disorders
mandates a focused screening and thorough differential diagnosis
to rule out other potential causes of urgency/frequency and/or
pelvic pain symptoms that characterize this condition. In addition
to a history and physical examination, urinalysis and urine culture
are the ﬁrst steps in ruling out disorders that mimic IC/PBS, such as
urinary tract infection and bladder cancer. The absence of bacteriaor blood cells in a voided urine specimen is characteristic of IC/PBS.
Other specialized examinations aiding in the diagnosis of IC/PBS
include a potassium sensitivity test (PST), cystoscopy with bladder
hydrodistention, and UDS.
Screening tools for IC/PBS include the Pelvic Pain and Urgency/
Frequency Patient Symptom Scale and O’Leary-Sant IC Symptom
Index and IC Problem Index, which may describe the nature and
severity of the disease. However, none of these has been shown to
be of value for diagnosis [16,17].
4.1. Potassium sensitivity test
The PST is a sensitive indicator of bladder dysfunction that can
be performed in a clinician’s ofﬁce [18]. The PST is based on the
premise that, unlike healthy bladder walls, the altered GAG epi-
thelium in IC/PBS will allow potassium [instilled directly into the
bladder as a 0.4 M potassium chloride (KCl) solution] to pass into
the bladder. If it is able to pass through the bladder wall, the po-
tassium, which is an irritant, will trigger a pain response and/or
a sense of urgency. Up to 90% of patients diagnosed with IC/PBS
have positive PSTs, as do 81% of gynecological patients with pelvic
pain; less than 2% of healthy women experience pain or urgency
symptoms during a PST [16,19]. However, a PST cannot, on its own,
reliably distinguish IC/PBS from other disorders of bladder origin
[18].
4.2. Cystoscopy with bladder hydrodistention
The cystoscopic ﬁndings in IC/PBS consist of glomerulations,
maximal bladder capacity under anesthesia, or Hunner’s ulcers.
Although the presence of submucosal hemorrhages or glomer-
ulations on cystoscopy is part of the National Institute of Diabetes
and Digestive and Kidney Diseases research parameters for the
diagnosis of IC/PBS, it is not predictive of pathology and does not
correlate with symptoms; a biopsy is not diagnostic of IC/PBS and
the presence of glomerulations is not speciﬁc for IC/PBS [20]. The
primary indication for cystoscopy in the assessment of pelvic pain
is to rule out malignancy in patients with hematuria and/or
abnormal urinary cytology. Cystoscopy is no longer widely used as
a standard diagnostic procedure in suspected IC/PBS.
4.3. Biomarkers
Interest in the mechanism of bladder repair from tissue damage
has led to the identiﬁcation of several potential biological markers
that might prove valuable for identifying IC/PBS from urine sam-
ples. Although the list of urinary factors tested as biomarkers of IC/
PBS is relatively longdincluding norepinephrine, substance P,
kallikrein, GAG, and mast cell mediatorsdthe most likely current
candidates to establish a diagnosis of IC/PBS early in the course of
the disorder are antiproliferative factor [21], nerve growth factor
[22], and glycoprotein-51 [23].
5. Urodynamic study and interstitial cystitis/painful bladder
syndrome
UDS is a group of tests under ﬂuoroscopy used to assess the
function and morphology of the urinary tract by measuring various
aspects of urine storage and evacuation. UDS has been widely used
to aid in understanding the physiological mechanisms of lower
urinary tract dysfunction [24]. However, there is a paucity of cur-
rent literature addressing urodynamics and its role in IC/PBS. The
current paradigm for IC/PBS diagnosis relies mainly on a history
and physical examination and places less emphasis on diagnostic
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UDS for routine clinical use to establish a diagnosis of IC/PBS [10].
The characteristic UDS ﬁndings in IC/PBS patients include an
early ﬁrst sensation of ﬁlling (FSF) and small cystometric bladder
capacity (CBC) [26e28]. Although the ﬁndings of UDS are not
pathognomonic for IC/PBS, theymay provide information regarding
concomitant voiding dysfunction in IC/PBS patients and can aid in
detection of bladder outlet obstruction, poor detrusor contractility,
and other conditions that could explain why patients are initially
refractory to ﬁrst-line therapy [10]. In addition, UDS variables have
been shown to be correlated with clinical symptoms, the results of
PST, and cystoscopic ﬁndings in IC/PBS patients.
5.1. Correlation between urodynamic study parameters and clinical
symptoms
Kirkemo et al evaluated the association of symptoms and cys-
tometric ﬁndings in the ICDB study [29]. They found that the ﬁrst
sensation to void andmaximal cystometric capacity correlatedwith
frequency, urgency, and nocturia as measured by voiding diaries,
visual analog scales (VAS), and a quality-of-life questionnaire. A
recent study by Kuo et al showed in detail that UDS parameters,
such as the FSF, ﬁrst desire to void (FD), strong desire to void (SD),
CBC, and voided volume (VV) were signiﬁcantly associated with the
severity of clinical symptoms measured by the IC symptom index
and IC problem index [28].
5.2. Correlation between urodynamic study parameters and
potassium sensitivity test
Although previous studies failed to ﬁnd a relationship between
cystometric parameters and a positive PST in IC/PBS patients
[30,31], a recent study evaluating 214 IC/PBS patients demonstrated
that subjects with a positive PST had lower mean volumes at SD,
CBC, and VV, and thus a low maximum ﬂow rate (Qmax) [28].
Although a positive PST may be rendered in conditions other than
IC/PBS [32], it can still indicate more severe urothelial dysfunction
that is more susceptive to the stimulation of KCl, thus resulting in
volume reduction of the bladder in IC/PBS patients [28].
5.3. Correlation between urodynamic study parameters and
cystoscopic hydrodistention
Nigro et al reported that the volume at maximum capacity on
urodynamics was positively associated with the volume during
hydrodistention [33]. Recently the study reported by Kuo et al not
only supported their ﬁndings, but also identiﬁed other UDS pa-
rameters (FSF, FD, SD, Qmax, and VV) that were positively correlated
with anesthetic maximal bladder capacity [28]. Furthermore, their
study also implied the severity of glomerulations is negatively
correlated with the bladder volume measured objectively as UDS
parameters (FSF, FD, SD, CBC, and VV). More advanced disease
progression involving neovascularizationand possible neurogenic
inﬂammation of the bladder may lead to an unpleasant sensation
during bladder ﬁlling and thus limit bladder capacity [28]. The
mechanism of glomerulations and its correlation with IC/PBS are
not, however, fully understood and need investigation.
5.4. Combined urodynamic study and potassium sensitivity test
may help in the diagnosis of interstitial cystitis/painful bladder
syndrome in female patients
Our recent study consisting of 405 women with increased
bladder sensation and 272 symptomatic controls [34] demon-
strated that a diagnosis of deﬁnite IC/PBS could be highly suspectedin womenwith frequency urgency and pain symptoms, a small CBC
of less than 350 mL on UDS, and a positive PST, especially when the
PST response of painwas2 on a VAS. A positive predictive value of
100% can be achieved if we choose women for cystoscopic hydro-
distention based on these clinical ﬁndings; even when the pain
response was 1 on a VAS, the positive predictive value was 91.2%
[34].
6. Conclusion
Although the value of UDS in the diagnosis of IC/PBS remains
inconclusive, previous studies have demonstrated correlations of
UDS parameters with clinical symptoms, the results of PST, severity
of glomerulations, and maximal bladder capacity during cysto-
scopic hydrodistention. In addition, a recent study showed that
a combination of UDS and PST may aid in differentiating IC/PBS in
women with increased bladder sensation. All of these results sug-
gest that there might be a role for UDS in the diagnosis of IC/PBS.
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